Specialized Pain Focus Zalicus specializes in the discovery and development of novel therapeutics for pain management, particularly targeting neuropathic, inflammatory, and acute pain, which presents opportunities to collaborate or supply to pharmaceutical companies seeking innovative pain solutions.

Clinical-stage Portfolio With a portfolio comprising proprietary clinical-stage candidates like Z160 and Z944, Zalicus offers a unique opportunity to partner with companies interested in advancing or licensing early to mid-stage pain treatments.

Strategic Collaborations Zalicus has established multiple revenue-generating partnerships with large pharmaceutical firms, indicating a potential pathway for business development through licensing, co-development, or technology sharing agreements.

Tech-Driven Discovery Utilizing high throughput screening and ion channel modulation expertise, Zalicus can be a valuable partner for companies looking to augment their drug discovery pipelines with specialized, innovative biotechnologies.

Growing Yet Niche Despite a smaller scale with revenue between 1 million and 10 million and a team under 50 employees, Zalicus’s niche focus on pain therapeutics positions it as a strategic collaborator for targeted biotech and pharma companies expanding their pain management portfolios.